Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reid W Merryman

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Transplantation and Cellular Therapy|May 22, 2026
Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic LymphomaTaha Al-Juhaishi, Kwang Woo Ahn, Tiening Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Blood|September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphomaLorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Blood|September 27, 2021
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remissionMazyar Shadman, Marcelo Pasquini, Kwang Woo Ahn, et al.
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Transplantation and Cellular Therapy|May 22, 2026
Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic LymphomaTaha Al-Juhaishi, Kwang Woo Ahn, Tiening Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Blood|September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphomaLorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Blood|September 27, 2021
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remissionMazyar Shadman, Marcelo Pasquini, Kwang Woo Ahn, et al.
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.
Pageof 5